Tackling the most impactful AI challenge of our time:
A novel hybrid approach to predict drug safety
.png)
Pharma's first AI safety prediction platform
Drug development is expensive, with 89% of drugs ultimately failing in clinical trials. Quris aims to address the trillion-dollar challenge that other unicorn AI-Pharma companies have not: Predicting which drug candidate will safely work in humans. More…
Machine-Learning Trained by Patients-on-a-Chip
Our unique machine-learning approach generates data for classification algorithms by testing drugs on miniaturized Patients-on-a-Chip and then the machine-learning model is trained using this automatically-tagged data. More…
An All-Star Team
Based in Boston and Tel-Aviv, Quris is led by a stellar team of pioneers in machine-learning, big-data, genomics, technology, and medical device development - all with a strong track record of success, including Moderna co-founder Robert Langer and Nobel Laureate Aaron Ciechanover. More…
Based in Boston and Tel-Aviv, Quris is led by a stellar team of pioneers in machine-learning, big-data, genomics, technology, and medical device development - all with a strong track record of success, including Moderna co-founder Robert Langer and Nobel Laureate Aaron Ciechanover. More…
As featured in
Merck KGaA, Darmstadt, Germany and Quris-AI Expand Collaboration
Quris-AI on Inside The Blueprint
2023 forecast: An ‘inflection point’ for biopharma
Quris Closes $28 Million in Seed Funding From Top Institutional Investors
The AI pharmacist